E-LIB Suche - Ergebnisse für: Lin, Lishi

1

Treatment patterns and survival outcomes of patients admitt..:

Lin, Lishi ; Houwink, Aletta P. I. ; van Dieren, Jolanda M....
Cancer Medicine. 13 (2024) 12 - p. , 2024

Link: https://doi.org/10.1002/..

2

Impact of bariatric surgery on oral anticancer drugs: an an..:

Lau, Cedric ; Mohmaed Ali, Ma Ida ; Lin, Lishi...
Cancer Chemotherapy and Pharmacology. 94 (2024) 1 - p. 25-34 , 2024

Link: https://doi.org/10.1007/..

3

Investigation on Well Interferences of Infill Well Fracturi..:

Tang, Xuanhe ; Yang, Haixin ; Zhu, Haiyan...
Rock Mechanics and Rock Engineering. , 2024

Link: https://doi.org/10.1007/..

4

A joint model of longitudinal pharmacokinetic and time-to-e..:

Lin, Lishi ; van der Noort, Vincent ; Steeghs, Neeltje...
Cancer Chemotherapy and Pharmacology. , 2024

Link: https://doi.org/10.1007/..

5

Clinical Relevance of High Plasma Trough Levels of the Kina..:

Lin, Lishi ; Barkman, Hannerieke J. ; Smit, Egbert F....
Therapeutic Drug Monitoring. 46 (2023) 1 - p. 73-79 , 2023

Link: https://doi.org/10.1097/..

6

Are novel oral oncolytics underdosed in obese patients?:

Lin, Lishi ; van der Meer, Ellen K. O. ; Steeghs, Neeltje..
Cancer Chemotherapy and Pharmacology. 93 (2023) 2 - p. 129-136 , 2023

Link: https://doi.org/10.1007/..

7

Longitudinal nonlinear mixed effects modeling ofEGFRmutatio..:

Janssen, Julie M. ; Verheijen, Remy B. ; van Duijl, Tirsa T....
Clinical and Translational Science. 15 (2022) 8 - p. 1916-1925 , 2022

Link: https://doi.org/10.1111/..

8

The influence of body mass index on the tolerability and ef..:

Lin, Lishi ; Soesan, Marcel ; van Balen, Dorieke E. M...
Breast Cancer Research and Treatment. 195 (2022) 3 - p. 325-331 , 2022

Link: https://doi.org/10.1007/..

9

Representativeness of Phase III Trial for Osimertinib in Pr..:

Lin, Lishi ; Smit, Egbert F. ; de Langen, Adrianus J....
Targeted Oncology. 17 (2021) 1 - p. 53-59 , 2021

Link: https://doi.org/10.1007/..

10

Longitudinal nonlinear mixed effects modeling of EGFR mutat..:

Janssen, Julie M ; Verheijen, Remy B ; van Duijl, Tirsa T...
Clinical and Translational Science, 1752-8054, 2022, 15:8, s. 1916-1925. , 2022

Link: http://urn.kb.se/resolve..

11

Longitudinal nonlinear mixed effects modeling of EGFR mutat..:

Janssen, Julie M ; Verheijen, Remy B ; van Duijl, Tirsa T...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372429/. , 2022

Link: http://www.ncbi.nlm.nih...

12

The influence of body mass index on the tolerability and ef..:

Lin, Lishi ; Soesan, Marcel ; van Balen, Dorieke E. M..
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464742/. , 2022

Link: http://www.ncbi.nlm.nih...

13

Representativeness of Phase III Trial for Osimertinib in Pr..:

Lin, Lishi ; Smit, Egbert F ; de Langen, Adrianus J...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783869/. , 2021

Link: http://www.ncbi.nlm.nih...

14

Longitudinal nonlinear mixed effects modeling of EGFR mutat..:

Julie M. Janssen ; Remy B. Verheijen ; Tirsa T. vanDuijl...
https://doi.org/10.1111/cts.13300. , 2022

Link: https://doi.org/10.1111/..

15

Contribution of robust transitional interface featuring Mg ..:

Zhu, Lin ; Ma, Lishi ; Zhao, Dongdong...
Composites Communications. 48 (2024) - p. 101908 , 2024

Link: https://doi.org/10.1016/..